Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage - 14/12/19
, Grant Walliser, PharmD a , M. Chance Spalding, DO, PhD b , Michelle Pershing, PhD c , Michelle Kincaid, MD b Abstract |
Objective |
The objective of this study was to determine the effectiveness and safety of four-factor prothrombin complex concentrate (4F-PCC) for the reversal of factor Xa inhibitors in patients with traumatic intracranial hemorrhage (ICH).
Methods |
This was a retrospective cohort study of patients taking factor Xa inhibitors with traumatic ICH between March 1, 2015 and August 31, 2017 at two trauma centers. The primary outcome was in-hospital mortality in patients who received 4F-PCC (4F-PCC group) compared to those who did not (no reversal group). Secondary outcomes included functional recovery, hospital and intensive care unit (ICU) length of stay (LOS), and thromboembolic complications.
Results |
There were 62 patients included in the study. Injury Severity Score (ISS) was significantly higher in the 4F-PCC group (17.6 vs. 12.1, p = 0.019). The 4F-PCC group had a significantly higher mortality (22.9% vs. 3.7%, p = 0.034) and longer ICU LOS (2.5 vs. 1.4 days, p = 0.0024). The no reversal group had a significantly higher incidence of ischemic stroke/transient ischemic attack (TIA) (0% vs. 14.8%, p = 0.019). After controlling for ISS, there was no significant difference in mortality (p = 0.20), ICU LOS (p = 0.64), or ischemic stroke/TIA (p = 0.94). There was no difference in hospital LOS, discharge disposition, final Activity Measure for Post Acute Care daily activity score, VTE, or MI.
Conclusion |
Patients with a higher ISS received 4F-PCC preferentially, which led to an apparent mortality benefit the no reversal group. After adjusting for baseline differences between groups, there was no difference in mortality, functional recovery, hospital and ICU LOS, or thromboembolic complications.
Le texte complet de cet article est disponible en PDF.Keywords : Factor Xa inhibitor, Four-factor prothrombin complex concentrate, Intracranial hemorrhage, Trauma
Plan
| ☆ | This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This work was presented as a poster at the ASHP Midyear Clinical Meeting on December 6, 2017 and as a brief lecture at the Great Lakes Pharmacy Resident Conference on April 26, 2018 and the OhioHealth Research Symposium on May 23, 2018. |
Vol 37 - N° 10
P. 1907-1911 - octobre 2019 Retour au numéro
Article précédent
- A comparison of call volumes before, during, and after Hurricane Harvey
- Andrew S. Crutchfield, Kent Alan Harkey
- Pentraxin-3: A strong novel biochemical marker for appendicitis in children
- Mustafa Onur Oztan, Aysegul Aksoy Gokmen, Tunc Ozdemir, Tuba Müderris, Selcuk Kaya, Gokhan Koyluoglu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?